Skip to main content

Table 1 Baseline characteristics of enrolled patients

From: Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience

Characteristics Total PCCs (82) PBMNCs (78) P
Age, years 41.2 (11.2) 40.6 (10.5) 41.8 (11.8) .610
Male, n (%) 157 (98.1) 80 (97.6) 77 (96.3) .990
BMI, kg/m2 23.2 (3.7) 23.5 (3.5) 22.9 (3.8) .820
Etiology
 TAO, n (%) 155 (96.9) 79 (96.3) 76 (97.4) 1.000
 Eosinophilia, n (%) 1 (0.63) 0 (0) 1 (1.30) .487
 SLE, n (%) 3 (1.88) 2 (2.4) 1 (1.3) 1.000
 Erythema nodosum, n (%) 1 (0.63) 1 (1.2) 0 (0) 1.000
Comorbidities
 Smoking, n (%) 145 (90.6) 72 (87.8) 73 (93.6) .210
 Hypertension, n (%) 8 (5.0) 5 (6.1) 3 (3.8) .720
 Type II diabetes mellitus, n (%) 8 (5.0) 4 (4.9) 4 (5.1) .990
 Hyperlipidemia, n (%) 11 (6.88) 7 (8.5) 4 (5.1) .394
 Coronary artery disease, n (%) 3 (1.88) 2 (2.4) 1 (1.3) .990
Treated limbs
 Upper/lower extremity, n 5/155 3/79 2/76 .990
 Right/left, n 86/74 44/38 42/36 .989
 Ulcer only, n (%) 75 (46.9) 34 (41.5) 41 (52.6) .160
 Gangrene, n (%) 70 (43.8) 37 (4.1) 33 (42.3) .720
Rutherford class
 4, n (%) 15 (18.3) 11 (13.4) 4 (5.1) .720
 5, n (%) 145 (90.6) 71 (86.6) 74 (94.9) .720
Medication history
 Aspirin, n (%) 134 (83.8) 66 (80.5) 68 (87.2) .251
 Clopidogrel, n (%) 18 (11.3) 10 (12.2) 8 (11.2) .698
 Cilostazol, n (%) 61 (38.1) 32 (39.0) 29 (37.2) .810
 Prostaglandins, n (%) 124 (77.5) 61 (74.4) 63 (80.8) .334
 Warfarin, n (%) 6 (3.8) 4 (4.9) 2 (2.6) .682
 Rivaroxaban, n (%) 5 (3.1) 2 (2.4) 3 (3.8) .676
Surgical history
 Bypass, n (%) 18 (11.3) 11 (13.4) 7 (9.0) .374
 Endarterectomy, n (%) 5 (3.1) 3 (3.7) 2 (2.6) 1.000
 PTA, n (%) 42 (26.3) 20 (24.2) 22 (28.2) .584
 Stenting, n (%) 16 (10.0) 8 (9.8) 8 (10.3) .916
 Thrombolysis, n (%) 52 (32.5) 28 (34.1) 24 (30.8) .648
 Sympathectomy, n (%) 7 (4.4) 2 (2.4) 5 (6.4) .268
 Surgical thrombectomy, n (%) 22 (13.8) 12 (14.6) 10 (12.8) .739
 Excimer laser thrombectomy, n (%) 7 (4.4) 2 (2.4) 5 (6.4) .268
  1. PCCs purified CD34+ cells, PBMNCs peripheral blood mononuclear cells, BMI body mass index, TAO thromboangiitis obliterans, SLE systemic lupus erythematosus, PTA percutaneous transluminal angioplasty